The Impact of Achondroplasia on Quality of Life, Healthcare Resource Use, Clinical, Socio-economic and Psychosocial state of the Individual (LIAISE)

First published: 23/01/2017

**Last updated:** 14/01/2021





### Administrative details

EU PAS number	
EUPAS17347	
Study ID	
39022	
DARWIN EU® study	
No	
Study countries	
Austria	
☐ Denmark	
Germany	

Italy		
Spain		
Sweden		

### **Study description**

Observational studylooking at the burden of illness in achondroplasia patients aged 5-70. The study will include a 5 year review of historical clinical data as well as a a single point collection of questionnaire data to look at the impact on the following in individuals with achondroplasia versus a normative population: - Quality of life - Clinical burden - Healthcare resource use Socio-economic burden - Psychosocial burden Up to 300 subjects will be included in 13 sites in Germany, Austria, Spain, Italy, Denmark and Sweden

### **Study status**

Finalised

### Research institutions and networks

### **Institutions**

### **BioMarin Pharmaceuticals**

First published: 01/02/2024

**Last updated:** 01/02/2024

Institution

# Multiple centres: 13 centres are involved in the study

### Contact details

### **Study institution contact**

Director Program medinfoeu@bmrn.com

Study contact

medinfoeu@bmrn.com

### **Primary lead investigator**

**Director Program** 

**Primary lead investigator** 

# Study timelines

### Date when funding contract was signed

Planned: 03/11/2016

Actual: 03/11/2016

### Study start date

Planned: 30/10/2017

Actual: 22/12/2017

### Data analysis start date

Planned: 28/04/2018

Actual: 31/08/2018

### Date of interim report, if expected

Planned: 29/06/2018

Actual: 19/10/2018

#### Date of final study report

Planned: 14/08/2020

Actual: 19/11/2020

# Sources of funding

• Pharmaceutical company and other private sector

### More details on funding

BioMarin Pharmaceutical Inc

# Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

Study type

Study type list

#### **Study topic:**

Disease /health condition

#### Study type:

Non-interventional study

### Scope of the study:

Disease epidemiology

#### **Data collection methods:**

Combined primary data collection and secondary use of data

### Main study objective:

The objectives of the study are to describe the impact on the following in individuals with achondroplasia versus a normative population in Denmark, Germany, Spain and Sweden: • Quality of life • Clinical burden • Healthcare resource use • Socio-economic burden • Psychosocial burden

## Study Design

### Non-interventional study design

Cross-sectional

Other

### Non-interventional study design, other

Retrospective

# Study drug and medical condition

#### Medical condition to be studied

Dwarfism

# Population studied

### Short description of the study population

Achondroplasia patients aged 5-70 years.

### Age groups

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

### Special population of interest

Other

### Special population of interest, other

Achondroplasia patients

### **Estimated number of subjects**

300

## Study design details

#### **Outcomes**

1. Patient Reported Outcomes (PRO) and Activities of Daily Living (ADL)2. Clinical burden for at least the last five years3. Healthcare resource use for at least the last five years 4. Socio-economic burden5. Psychosocial burden

#### **Data analysis plan**

Statistical analysis will be carried out using SAS software. An interim analysis will be performed after nine months of enrolment. Continuous variables will be described (distribution) by their mean, standard deviation, median, quartiles one and three, extreme values (minimum and maximum) and the number of missing data and will be compared to normative data. Categorical variables will be described (counts) by the absolute and relative (%) frequency of each class, and the number of missing data and will be compared to normative data.

# Data management

### **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

**Data sources (types)** 

Other

#### Data sources (types), other

Prospective patient-based data collection, Historical data from clinical records

# Use of a Common Data Model (CDM)

### **CDM** mapping

No

### Data quality specifications

#### **Check conformance**

Unknown

### **Check completeness**

Unknown

### **Check stability**

Unknown

### **Check logical consistency**

Unknown

### Data characterisation

#### **Data characterisation conducted**

No